ReviewVaccines2021
The Evolution of Cancer Immunotherapy.
Review in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic significance of tumoral Siglec-15 expression in solid tumors: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- The glycolysis-H4K12la-PKM2 positive feedback loop drives M2 polarization of macrophages in colorectal cancer.Clinical epigenetics · 2026Article
- Propolis-loaded liposomes (ProLip) enhance macrophage-mediated immunomodulation and suppress breast cancer cell proliferation.Scientific reports · 2025Article
- Visual presentation of age differences in relative survival of hematological neoplasms in Sweden and the neighboring countries.Annals of hematology · 2025Article
- OX40/OX40L: a new target for tumor immunotherapy and its clinical research progress.Frontiers in oncology · 2025Review
- Advances in cancer immunotherapy: Strategies and innovations strategies for adoptive immunotherapy of cancer.Iranian journal of basic medical sciences · 2025Review
- Tumor microenvironment and immune-related myositis: addressing muscle wasting in cancer immunotherapy.Frontiers in immunology · 2025Review
- Harnessing Artificial Intelligence for the Detection and Management of Colorectal Cancer Treatment.Cancer prevention research (Philadelphia, Pa.) · 2024Review
- Review
- DIRMC: a database of immunotherapy-related molecular characteristics.Database : the journal of biological databases and curation · 2024Article
- Global trends in tumor microenvironment-related research on tumor vaccine: a review and bibliometric analysis.Frontiers in immunology · 2024Review
- Review
- Survival in hematological malignancies in the Nordic countries through a half century with correlation to treatment.Leukemia · 2023Article
- Advances in immunotyping of colorectal cancer.Frontiers in immunology · 2023Review
- A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells.Frontiers in immunology · 2023Article
- T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications.Frontiers in immunology · 2023Review
- Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial.Frontiers in pharmacology · 2022Article
- The Interaction Between the Microbiome and Tumors.Frontiers in cellular and infection microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Immunotherapy has changed the environment of cancer treatment by providing new and efficacious therapy options for many solid and hematologic malignancies. Although not a new field of oncology, immunotherapy has quickly developed into one of the most flourishing fields in medicine. In this review article, we explore key discoveries which helped to shape our current understanding of the immune system's role in neoplasms. Many landmark developments include the advancements in checkpoint inhibitors, monoclonal antibodies, CAR-T cells and anti-cancer vaccines. We also explore the drawbacks and efficacy of various categories of immunotherapy. Ongoing investigations within immunotherapy, such as the gut microbiome, combining checkpoint inhibitors and gene sequencing, continue to personalize treatments for cancer patients, providing exciting and endless possibilities for the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.